New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
12:25 EDTGMED, COV, WMGI, SNN, SYK, NUVA, ARTC, ZMH, JNJAnother bidder may emerge for ArthroCare, says William Blair
William Blair says it would not be surprised to see another bidder emerge for ArthroCare (ARTC). The firm lists Johnson & Johnson (JNJ) and Stryker (SYK)) as the most likely to submit a competing bid to Smith & Nephew's (SNN), and notes Biomet, Zimmer (ZMH) and Covidien (COV) could also have interest in the company. Should the deal for ArthroCare close as currently contemplated, William Blair thinks peers Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI) could be takeover targets.
News For ARTC;SNN;GMED;NUVA;WMGI;JNJ;SYK;COV;ZMH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 25, 2015
16:20 EDTGMEDGlobus Medical reports Q4 adjusted EPS 30c, consensus 25c
Subscribe for More Information
14:47 EDTJNJPharmacyclics could fetch as much as $19B in sale, FT says
Pharmacyclics (PCYC) is considering a sale that could fetch as much as $19B, reported Financial Times, citing people familiar with the matter who said Johnson & Johnson (JNJ) is exploring a potential deal for the company. The Fly notes that Bloomberg had a similar report, but its report said Pharmacyclics could fetch $17B-$18B in a sale. Reference Link
14:10 EDTJNJPharmacyclics downgraded to Hold on lack of upside at Deutsche Bank
Subscribe for More Information
12:54 EDTJNJPharmacyclics exploring options including sale, Bloomberg reports
According to sources, Pharmacyclics (PCYC), which develops cancer treatments, is currently exploring options, Bloomberg reports. One option may include a sale of the company, and the sources say Johnson & Johnson (JNJ) and Novartis (NVS) have expressed interest in the company. Pharmacyclics could fetch $17B-$18B in a sale, the sources add. Reference Link
12:53 EDTJNJPharmacyclics weighing sale to U.S. drugmaker, Bloomberg reports
Subscribe for More Information
February 24, 2015
16:30 EDTNUVANuVasive announces updated Non-GAAP definition
NuVasive announced that it will implement an updated non-GAAP definition in Q1. NuVasive will redefine its non-GAAP cost of goods sold, gross margin, operating expenses, operating margin and earnings per share financial measures from its existing non-GAAP definition to include the impact of non-cash stock-based compensation and certain intellectual property related litigation expenses, both of which had previously been excluded in the company's calculation of these non-GAAP financial measures. In addition to GAAP results, these non-GAAP measures are intended to provide additional information to enable investors to assess the Company's operations in the same way management assesses operations. Management uses non-GAAP measures to budget, evaluate and measure the company's performance and sees these results as an indicator of the company's ongoing business performance. The company believes these changes in non-GAAP reporting increase transparency and better reflect the underlying financial performance of the business. CFO Quentin Blackford said, "This update allows us to provide investors with a meaningful non-GAAP measurement that represents the performance of our core business on a more inclusive, comprehensive basis. Importantly, this change does not impact NuVasive's plan to deliver at least 100 basis points of operating margin expansion each year, as well as improved EBITDA margins for the next several years as we rapidly scale the business in the U.S. and internationally and capture well-identified opportunities to drive profitability."
16:18 EDTNUVANuVasive sees FY15 adjusted EPS approximately $1.10, consensus $1.53
Sees FY15 revenue approximately $810M, consensus $811.03M, which includes an approximate $10M of currency headwinds.
16:16 EDTNUVANuVasive reports Q4 adjusted EPS 39c, consensus 37c
Reports Q4 revenue $204.3M, consensus $201.39M.
February 22, 2015
12:51 EDTJNJJ&J considers Cordis sale with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
February 20, 2015
17:31 EDTJNJJ&J considering sale of Cordis with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
16:03 EDTJNJOptions Update; February 20, 2015
Subscribe for More Information
09:38 EDTJNJActive equity options trading on open
Subscribe for More Information
08:27 EDTSYKStryker has a conference call hosted by JPMorgan
Subscribe for More Information
07:23 EDTJNJAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
February 18, 2015
16:46 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
12:36 EDTJNJAnalysts applaud cheaper than expected Boston Scientific settlement
Subscribe for More Information
12:31 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
07:41 EDTJNJSettlement 'a big win' for Boston Scientific, says Bernstein
Subscribe for More Information
07:12 EDTJNJBoston Scientific settlement should remove overhang, says Stifel
Subscribe for More Information
07:09 EDTJNJBoston Scientific payment to J&J well below expectations, says Piper Jaffray
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use